“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity by Mamessier, Emilie et al.
“Stealth” tumors
Breast cancer cells shun NK-cells anti-tumor immunity
Emilie Mamessier,
1,3,* François Bertucci,
2,3 Renaud Sabatier,
2,3 Daniel Birnbaum
2,3 and Daniel Olive
2,3
1Centre d’Immunologie de Marseille-Luminy; Aix-Marseille Université; Campus du Luminy; Marseille, France;
2Centre de Recherche en Cancérologie de Marseille; INSERM;
Institut Paoli-Calmettes; Marseille, France;
3Aix-Marseille Université; UMR 891; Marseille, France
Keywords: NK cells, anti-tumor immunity, breast, immuno-editing, immunosurveillance
Breast cancers (BCs) comprise heterogeneous subtypes of various prognoses. An active anti-tumor immune profile
usually correlated with a better survival. Two current major challenges of BC research are to understand the inter-
relations between BC and anti-tumor immunity, and to identify candidates whose targeting would contribute to enhance
anti-tumor efficiency.
Innate immunity maintains poised police-
men such as natural killer (NK) cells that
recognize and destroy cells that turn into
troublemakers, as is the case of tumor cells.
NK-cells, but also other members of anti-
tumor immunity, have this natural ability
to distinguish normal cells from “modi-
fied” cancer cells through the expression of
inhibitory and activating receptors trig-
gered during target-cell recognition. The
majority of inhibitory receptors are specific
for the different HLA-class I molecules
expressed by most normal cells. The main
activating receptors recognize specific
ligands upregulated upon cellular stress,
a consequence of the genomic instability
that initiate and drive cancer, and/or
signals coming from the altered micro-
environment. Accordingly, NK-cells can
kill target cells that have lost or express
low amounts of HLA-class I molecules
and that express activating ligands, both
reported features of tumor cells.
When looking at the expression of NK-
cells ligands in breast cancer (BC) patients
to understand why immunity fails to con-
trol BC occurrence in otherwise healthy
individuals, we observed several patterns of
ligand expression.
1,2 Interestingly, these
patterns correspond to different molecular
subtypes, themselves characterized by dis-
tinct genomic alterations and originating
from different precursors.
3 The two major
BC subtypes are luminal and basal. We
observed that luminal BC express lower
levels of inhibitory and activating mole-
cules compared with healthy breast tissues,
suggesting a poor triggering of NK-cell
immunity, and certainly of the other
components of anti-tumor immunity as
well. In contrast, basal tumors express
both high levels of inhibitory ligands and
activating ligands. These differences sug-
gested that the phenotype of BC cells at
diagnosis was already the result of a more-
or-less successful immuno-editing process.
Interestingly, a major difference between
these two subtypes is disease evolution and
clinical outcome. Luminal, but not basal
BCs, express hormone receptors and can
be subdivided in luminal-A and luminal-B
BCs. Luminal-B BCs resist hormone
therapy and have a poor prognosis.
Luminal-B but not luminal-A BCs are
highly proliferative. Thus, within luminal
BCs, the main predictor of evolution is
proliferation, a feature resulting from
intrinsic genomic abnormalities and/or
the pro-inflammatory environment. Basal
BCs have an overall poor prognosis as
compared with luminal BCs. Basal BCs
are all highly proliferative and proliferation
is therefore neither a determinant nor a
predictor of their evolution. Nevertheless,
it is possible to identify subgroups of basal
BCs with a relatively better prognosis.
4
The latter are explicitly characterized by
the expression of genes involved in anti-
tumor immunity.
4-7 Thus, in basal BCs,
the main predictor of outcome is the anti-
tumor immune response. Why immune
response is not as an important predictor
of survival in luminal BCs may be because,
as mentioned earlier, the involvement of
anti-tumor immunity is not the same in
the two subtypes and the factor “pro-
liferation” (present in luminal-B but not in
luminal-A) eventually outperforms by far
the factor “immune response” in survival
analyses (Fig.1).
Nevertheless, at diagnosis, breast
tumors have evolved to become “invisible”
to anti-tumor immunity, and those with a
“higher” visibility seem to be of better
prognosis.
4 Most importantly, BC cells
seem to have acquired multiple tricks to
achieve invisibility and avoid anti-tumor
recognition. Indeed, the phenotypic and
functional analyzes of NK cells isolated
from progressive stages of BC patients
revealed that NK-cells are poorly func-
tional in most patients with invasive BC
only. These alterations were erased in
patients undergoing long-term remission
It appeared that: (1) tumor can induce its
own tolerance from NK-cells anti-tumor
immunity; (2) invasive characteristics
and metastasis occurrence are dependent
on the inhibition of NK-cell-mediated
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of others converge to show the importance
of immune response in limiting both
tumor growth and dissemination of meta-
static cells.
8-10
In addition, we have identified some of
the mechanisms possibly used by breast
tumor cells to shun NK cells. However, the
list remains open and includes so far:
inhibition through cell-cell contacts, secre-
tion of inhibitory factors, re-organization
of the tumor microenvironment, notably
with the increase of Treg recruitment
and facilitation of mesenchymal stem cell
growth. Such new surrounding environ-
ment contributes to support tumor growth
in situ or at the site of metastasis, kept
protected from immune recognition. Most
of these modifications are possible through
the massive secretion of TGFβ1, PGE2,a s
well as several metalloproteases responsible
for the downregulation of activating recep-
tors, the shedding of homing molecules or
surface beacons that are used as NK-cell
ligands, such as sMICA. This is not to
mention the direct involvement of these
molecules on disease progression, metastatic
potential and therapeutic resistance.
Altogether, our works show that BCs
leave little chance to anti-tumor immu-
nity, and especially NK cells, to efficiently
exert their primary functions. We have
demonstrated that when tumor cells
cannot be recognized or when the destruc-
tion power is altered, innate immunity
remain useless. “Stealth” BC cells can thus
safely leave the primary tumor site to
metastasize. However, in some cases, a
residual anti-tumor immunity might
be sufficient to tip the scale toward a
more favorable prognosis, even in usually
very aggressive tumors. The good news
Figure1. Involvement of proliferative factors and anti-tumor immunity in the Luminal and basal breast cancer subtypes, at diagnosis, and associated
prognosis. Luminal A are poorly proliferative and express low level of both activating and inhibitory receptors of anti-tumor immunity, resulting in a low
activation of anti-tumor immunity. Luminal B, which are of poor prognosis, are also poorly immunogenic, but are characterized by a strong proliferative
capacity. All basal BCs are highly proliferative and have an overall poor prognosis as compared with luminal BCs. Within basal BCs the cases with the
worst prognosis are poorly immunogenic despite the presence of activating ligands of anti-tumor immunity, certainly because of the strong expression
of inhibitory ligands and other inhibitory factors such as an increase in Treg recruitment. In this case, the tumor features allowing its proliferation are not
constrained, leading to its rapid evolution. A particular subgroup of basal BC can be identified by the presence of an active anti-tumor immune response
that can apparently outperform the factor “proliferation” and confer a surprisingly better prognosis to these patients.
366 OncoImmunology Volume 1 Issue 3is that, if tumor cells develop strategies
to overcome destruction by innate immu-
nity, we can elaborate counter-strategies
to restore NK-cells functions. Quite
surprisingly, this might be more efficient
through the targeting of strategies used to
escape NK-cells recognition rather than
the direct enhancement of anti-tumor
immune functions alone. However, con-
sidering the startling genomic variability
and associated tumorigenic features
observed in BCs, the best strategy might
certainly rely on combinatorial appro-
aches to successfully target such complex
disease.
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